Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 22/04/2024 BST 5-day change 1st Jan Change
66.95 USD +0.28% Intraday chart for Gilead Sciences, Inc. -1.18% -17.36%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cantor Fitzgerald Adjusts Gilead Sciences' Price Target to $75 From $78, Maintains Neutral Rating MT
Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says MT
BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89 MT
Leerink Partners Adjusts Gilead Sciences Price Target to $74 From $79 MT
US FDA mandates label updates on CAR-T cancer therapies RE
UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating MT
Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76 MT
Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP CI
Morgan Stanley Cuts Price Target on Gilead Sciences to $80 From $83, Keeps Equalweight Rating MT
Nurix Therapeutics, Gilead Sciences Extend Research Collaboration By 2 Years MT
Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration DJ
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences CI
Sector Update: Health Care Stocks Slide Late Afternoon MT
Top Midday Gainers MT
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures MT
Top Premarket Gainers MT
Gilead Sciences Files a Definitive Proxy Statement CI
Gilead Sciences Files a Definitive Proxy Statement CI
Gilead Sciences Files a Definitive Proxy Statement CI
Gilead Sciences Inc Receives a Shareholder Proposal from David Bahnsen CI
Gilead Sciences Inc Receives a Shareholder Proposal from John Chevedden CI
Gilead Sciences Inc Receives a Shareholder Proposal from Jing Zhao CI
Xilio Shares Take Flight Premarket After Gilead Deal DJ
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall MT
Gilead Says FDA Approves New Drug Application for Potential Hep-B Treatment for Smaller Children MT
Chart Gilead Sciences, Inc.
More charts
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
66.95 USD
Average target price
85.14 USD
Spread / Average Target
+27.17%
Consensus
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.
  5. Mizuho Securities Cuts Price Target on Gilead Sciences to $90 From $101, Maintains Buy Rating